Abstract: The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one Neisseria adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from a Neisseria meningitidis serogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.

Abstract: The disclosure relates to generally to the field of therapeutic and/or protective vaccination against Clostridium dificile (C. difficile). More specifically, it relates to methods for immunizing a host against C. difficile strains expressing C. difficile binary toxin (CDT) and strains not expressing CDT. These methods involve the administration to a host of an immunogenic composition comprising inactivated purified C. difficile Toxin A and purified Toxin B. The purified C. difficile toxins may be derived from a C. difficile strain that does not express CDT.

Abstract: Provided herein are compositions and methods for eliciting an immune response against Porphyromonas gingivalis. The compositions and methods relate to P. gingivalis polypeptides and fragments and variants thereof and the corresponding polynucleotides which are useful in the diagnosis, prevention and therapy of P. gingivalis infections (e.g. periodontitis). Antibodies against the polypeptides and compositions and methods including these antibodies are also disclosed. The disclosure also describes methods for the detection, prevention and treatment of P. gingivalis infection (e.g. periodontitis).